BioCentury Podcasts

・

頻道・共 2 個節目

生命科學

生命科學

每週更新
生命科學

生命科學

隔週更新

2 天前

Ep. 362 - AACR: Data and de-risking

Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year’s American Association for Cancer Research meeting in San Diego as biotechs unveiled their latest preclinical and first-in-human oncology data. On a special edition of the BioCentury This Week podcast, IQVIA Biotech CMO James Kyle Bryan joins BioCentury’s analysts to discuss what AACR revealed about modalities gaining traction, plus shares his perspective on de-risking clinical development and eliminating the “white space” that delays biotechs’ timelines in the clinic. This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech. View full story: https://www.biocentury.com/article/659235 #AACR #BispecificAntibodies #ADC #OncologyData #ClinicalDevelopment 00:01 - Sponsor Message: IQVIA Biotech 01:43 – AACR Early Signals 05:17 – Antibody Innovation 09:22 – Dual Payload ADCs 13:48 – De-Risking Drug Development 19:16 – Looking Ahead to ASCO To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

2 天前

・

25 分鐘
4 天前

Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers

The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDAQ-traded biotech and what could soon become the largest biotech IPO ever on NASDAQ. On the latest BioCentury This Week, BioCentury’s analysts discuss Eli Lilly's $3.25 billion takeout of in vivo CAR T company Kelonia, the market debut by obesity play Kailera and an upsized follow-on by Revolution on the back of its pancreatic cancer data. The analysts also discuss how autoimmune T cell engagers are diverging from their oncology roots and the potential implications of President Donald Trump’s executive order on psychedelic therapies. BioCentury’s analysts also take time to remember Sofinnova Partners’ Denis Lucquin, father of French biotech. This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech. View full story: https://www.biocentury.com/article/659183 #BiotechMA #BiotechIPO #CART #TCellEngagers #PsychedelicMedicine 00:01 - Sponsor Message: IQVIA Biotech 04:20 - Lilly's Kelonia Buy 10:31 - T Cell Engagers 23:07 - Psychedelics Executive Order 35:14 - CBER Director Search 37:37 - Public Markets Roundup 42:14 - Remembering Denis Lucquin To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

4 天前

・

44 分鐘
4月7日

Ep. 359 - 2Q markets preview, tariffs and biotech takeouts

Biotech has been resilient as the financial markets teeter under global volatility. For now, M&A and financings, if not IPOs, are continuing, but will the Mideast conflict halt biotech’s recovery? On the latest BioCentury This Week podcast, BioCentury’s Stephen Hansen breaks down the near-term and long-term outlook for a biotech industry hoping to continue the growth of 2H25. BioCentury’s analysts also discuss the impact of the Trump administration’s tariffs on the biopharma industry and last week’s biggest deals: the pending $6.3 billion takeout of Centessa by Eli Lilly and the proposed $5.6 billion acquisition of Apellis by Biogen. This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech. Register now as a delegate or apply to join the 2026 Presenting Company Class before the 26th Bio€quity Europe May 4-6 in Prague sells out. View full story: https://www.biocentury.com/article/659040 #BiotechMarkets #BiotechMA #GlobalVolatility #DrugPricingPolicy #BiopharmaStrategy 00:01 - Sponsor Message: IQVIA Biotech 05:09 - 2Q26 Preview 17:09 - Pharma Tariffs 24:04 - C-Path Initiative 26:32 - Lilly Deal 32:19 - Biogen Deal To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

4月7日

・

39 分鐘
4月14日

Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds

A pathway proposed by FDA to cut the time it takes biopharma companies to get to first-in-human trials is more ambitious than similar policies in Australia, China and the U.K. On the latest BioCentury This Week podcast, BioCentury’s analysts assess the proposal, as well as a concession for the biopharma industry on first-in-human studies in PDUFA reauthorization negotiations with FDA. The analysts also discuss the latest pair of billion-dollar biotech deals: Gilead's $3.2 billion takeout of antibody-drug conjugate company Tubulis and the acquisition of Soleno by Neurocrine for $2.9 billion for its Prader-Willi asset. Finally, BioCentury’s analysts discuss the new $6.3 billion Blackstone Life Sciences fund and the €1 billion vehicle unveiled last week by European VC Jeito Capital. This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech. View full story: https://www.biocentury.com/article/659127 #FDA #FirstInHuman #BiotechMergers #BiotechInvesting #LifeSciencesVC 00:01 - Sponsor Message: IQVIA Biotech 03:24 - FDA First-in-Human 11:44 - America First PDUFA Policy 17:43 - Gilead Buying Tubulis 23:41 - Blackstone's New Fund 28:37 - Jeito Capital 30:44 - Parker Institute To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

4月14日

・

34 分鐘
2025/08/12

Ep. 314 - Prasad, Lilly Obesity, Acadia & Biosecure

Phase III data from Lilly’s orforglipron in obesity fell short of investor expectations, but they appear to be enough to obtain approval and wide use. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss why the first-in-class oral small molecule GLP-1R agonist’s clean safety profile and clear manufacturing advantage over oral peptides give the product a leg-up in the market. They then discuss Vinay Prasad’s return to FDA after a brief hiatus, the revamped strategy of 32-year-old San Diego biotech Acadia Pharmaceuticals, and an attempt in the Senate to revive the Biosecure Act targeting China biotechs. Finally, the analysts preview this year’s Back to School package, which reimagines FDA. At a time of unprecedented change in government agencies, BioCentury’s 33rd Back to School asks what FDA could look like if it were reorganized from the ground up to create the regulator patients deserve and industry needs. View full story: https://www.biocentury.com/article/656727 #orforglipron #CBER #VinayPrasad #AcadiaPharmaceuticals 00:00 - Introduction 00:49 - Prasad 07:09 - Back to School 12:29 - Lilly Obesity 21:58 - Acadia's Comeback 28:50 - Biosecure Act To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

2025/08/12

・

39 分鐘
4月17日

Ep. 107 - Forbion’s Slootweg on Europe Biotech, NewCos From Asia and Green Investing

The European biotech ecosystem has gone through a substantial maturation process over the past 20 years, as VC funds such as Forbion have experienced exponential growth to fund the region’s innovation. But Forbion co-founder and managing director Sander Slootweg says there’s still more that can be done to fund future European innovations and improve Europe’s competitiveness globally. “We’ve observed in Europe that although we see great science, and we’ve been able to build great companies, in terms of the absolute magnitude of the ecosystem, we’re still lagging behind the U.S., and also China is coming up quickly,” Slootweg said in conversation with BioCentury's Stephen Hansen. View full story: https://www.biocentury.com/article/659150 #EuropeanBiotech #VentureCapital #BiotechFunding #Bioeconomy #GlobalInnovation 00:00 - Introduction 01:34 - Forbion’s growth 05:35 - Deal flow in Europe 10:20 - Green Investing 14:24 - Sourcing Asia Deals 22:20 - Unlocking the EU’s Capital 27:54 - Speeding Up Trials 30:13 - Building a Thriving EU Market 34:38 - Central & Eastern Europe

4月17日

・

38 分鐘
3月9日

Ep. 353 - Prasad Departure and Future of Fibrosis Therapies

The second ousting of Vinay Prasad from FDA in the past eight months won’t lead to major changes at the agency, other than selecting a successor tasked with keeping FDA out of the news ahead of the coming midterm elections. On the latest BioCentury This Week podcast, Washington editor Steve Usdin lays out why the former CBER director was pushed out at FDA and what’s next for the agency following his departure. BioCentury’s editors also discuss the next wave of therapies for idiopathic pulmonary fibrosis, including whether new candidates might go beyond slowing disease to halt or even reverse progression, the biological complexity that makes fibrosis so challenging, and what the 20-plus Phase II programs could teach the field about fibrosis biology. Also up for discussion were recent clinical wins — as well as more complicated readouts — from psychedelic therapies; plus the latest data updates from obesity treatments, with a focus on amylin agonists. View full story: https://www.biocentury.com/article/658698 #FDA #IdiopathicPulmonaryFibrosis #PsychedelicTherapies #ObesityDrugs #AmylinAgonists 00:00 - Introduction 01:56 - Prasad's Departure 15:27 - Fibrosis Therapies 23:35 - Psychedelics Clinical Catalysts 28:24 - Obesity Updates To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

3月9日

・

37 分鐘
3月30日

Ep. 357 - Deal-O-rama, Gilead and Tallon's U.K. vision

A flurry of deals, several with sizable upfront payments, has energized the biotech sector in March. On the latest BioCentury This Week podcast, BioCentury’s Paul Bonanos assesses last week’s deals by Merck, which is laying out $6.7 billion to acquire Terns, and Gilead, which is buying Ouro for about $1.7 billion up front. Gilead’s deal comes as the Foster City, Calif.-based biotech is looking to defend its position in HIV while resetting in inflammation and immunology and growing its oncology footprint through business development. BioCentury’s Lauren Martz analyzes the company’s pipeline following her recent conversation with CMO Dietmar Berger. Turning to the U.K., Editor in Chief Simone Fishburn details her conversation with CEO of MHRA, Lawrence Tallon, regarding what new reforms in the U.K. mean for drug developers and how he views initiatives helping to build the sector and place the U.K. in the race to become a destination for clinical trials. Rates for the 26th Bio€quity Europe May 4-6 in Prague increase after this week. Register now as a delegate or apply to join the 2026 Presenting Company Class before the conference sells out. View full story: https://www.biocentury.com/article/658974 #BiotechMA #BiopharmaStrategy #DrugDevelopment #UKBiotech #ClinicalTrials 00:00 - Introduction 01:09 - Merck Buying Terns 04:31 - Gilead, Galapagos Deal 09:35 - Growing Gilead 19:20 - Tallon's Vision for U.K. Biotech To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

3月30日

・

29 分鐘
2月3日

Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules

RNAi and exon-skipping therapies headline the list of regulatory and pivotal data catalysts in 2026, while new lipid-lowering mechanisms, modalities, and precision medicines define cardiovascular disease catalysts this year. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the most important milestones of the year in new modalities, CV and renal diseases. The analysts also discuss a new regulation in China introducing orphan drug exclusivity that could incentivize development of rare disease therapies. Dig into the BioCentury’s catalyst picks and the new China policy below • 2026 Catalysts: The rise of RNAi • 2026 Cardiovascular Catalysts: Lp(a) on the Horizon • 2026 Obesity Catalysts: Launches, readouts and challengers • 2026 Catalysts: Breakthrough progress in renal disease • AZ signals all-in on obesity via CSPC deal for $1.2B up front • China’s orphan drug exclusivity could bolster market, incentivize development View full story: https://www.biocentury.com/article/658286 00:00 - Introduction 02:28 - RNAi and Antisense Therapies 06:37 - Neuromuscular and Musculoskeletal 10:33 - Renal Disease Catalysts 22:26 - China's New Orphan Rules To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

2月3日

・

31 分鐘
4月2日

Ep. 358 - Europe's biotech challenge

Biotech innovators around the world are finding speed to be the driver for investment and partnering — speed to early human data and speed to de-risk assets. The new momentum from Asia, in particular China, has added a fresh challenge for European biotech on top of falling equity and R&D investment in Europe and a complex drug pricing landscape. On a special edition of the BioCentury This Week podcast on the eve of the 26th Bio€quity Europe conference, EQT Life Sciences' Christoph Broja and Prague Bio CEO Petra Kinzlová join BioCentury’s analysts to discuss the challenges faced by European biotech today and what the best strategy is to compete in this new era. Kinzlová also describes a growing biotech ecosystem in the Czech Republic, which will host Bio€quity Europe May 4-6. View full story: https://www.biocentury.com/article/659002 #EuropeanBiotech #ClinicalDevelopmentSpeed #ChinaBiotech #DrugPricing #BiotechInvestment 01:10 - Bio€quity Europe Preview 04:32 - Czech Innovation Hubs 09:52 - Pricing, Trials, Funding 13:07 - Fixing Trial Bottlenecks 17:49 - Pension Capital and Risk To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

4月2日

・

24 分鐘

BioCentury Podcasts leverage three decades of biopharma intelligence with thoughtful, accurate, and objective insights. BioCentury editors spotlight key scientific opinion leaders, corporate decision-makers, venture capitalists, and patient advocates, keeping you informed on the most current biotech stories and highlighting life science innovations.

網站

BioCentury Podcasts

熱門節目

Ep. 362 - AACR: Data and de-risking

Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers

Ep. 359 - 2Q markets preview, tariffs and biotech takeouts

Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds

Ep. 314 - Prasad, Lilly Obesity, Acadia & Biosecure

Ep. 107 - Forbion’s Slootweg on Europe Biotech, NewCos From Asia and Green Investing

Ep. 353 - Prasad Departure and Future of Fibrosis Therapies

Ep. 357 - Deal-O-rama, Gilead and Tallon's U.K. vision

Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules

Ep. 358 - Europe's biotech challenge

簡介

BioCentury Podcasts

熱門節目

熱門單集

簡介